Common Stock, par value $0.00001 per share
- Symbol
- KYTX
- Exchange
- NASDAQ
- Classification
- COMMON
- Status
- Current
Quarterly Report · 10-Q
KYTXNASDAQEQUITYCurrent
Kyverna Therapeutics, Inc. (Nasdaq: KYTX) is a late-stage clinical immunology company pioneering differentiated therapies with curative potential for neurologic autoimmune diseases. Kyverna’s lead autologous CD19-targeting CAR T-cell therapy candidate, miv-cel (mivocabtagene autoleucel, KYV-101), has demonstrated the potential to fundamentally change the treatment paradigm across multiple B-cell-driven autoimmune diseases. Kyverna is advancing its potentially first-in-class neuroimmunology franchise with its recently submitted Biologics License Application (BLA) for miv-cel in stiff person syndrome (SPS) and an ongoing registrational trial for generalized myasthenia gravis (gMG). Miv-cel has received three FDA Regenerative Medicine Advanced Therapy (RMAT) designations, in SPS, gMG, and non-active secondary progressive multiple sclerosis (naSPMS) based on compelling clinical data and significant unmet need, further reinforcing the therapy's potential across neuroimmunology. Additionally, the Company continues to advance new innovations that broaden access and choice for patients, expanding its leadership position in the field. For more information, please visit https://kyvernatx.com.
Kyverna Therapeutics, Inc. · 10-Q · Filed 2026-08-11